• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study
This study will provide important information about demographics, practice patterns, treatments, and associated outcomes in patients with AF. The results of this registry will also allow Brazilian data to be put in perspective with other AF registries across the world and provide opportunities to improve care of patients with AF in Brazil.
Source: American Heart Journal - March 9, 2016 Category: Cardiology Source Type: research

Prevalence and Outcome of Thrombotic and Embolic Complications in Adults after Fontan Operation
Conclusions TEC was not uncommon; risk factors for TEC were APC and atrial arrhythmias. Most patients were treated successfully with warfarin alone. A second TEC occurred in most patients whose anticoagulation was discontinued because of bleeding events.
Source: American Heart Journal - October 4, 2016 Category: Cardiology Source Type: research

Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED
Conclusions In VKA-experienced AF patients, the TIMI-AF score has limited usefulness predicting NCOs over a long-term period of follow-up. This novel score was not superior to CHA2DS2-VASc and HAS-BLED identifying ‘low risk’ AF patients.
Source: American Heart Journal - November 10, 2017 Category: Cardiology Source Type: research

Percutaneous Coronary Intervention and Antiplatelet Therapy in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin: Insights from the ARISTOTLE Trial
Conclusions PCI occurred infrequently during follow-up. The majority of patients on study drug at the time of PCI remained on study drug in the peri-PCI period; 19% continued the study drug without interruption. Antiplatelet therapy use post-PCI was variable, though the majority of patients received DAPT. Additional data are needed to guide the use of antithrombotics in patients undergoing PCI.
Source: American Heart Journal - November 10, 2017 Category: Cardiology Source Type: research

Efficacy and Safety of Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation in Relation to Renal Function Over Time – A RE-LY trial analysis
Conclusions In AF, WRF was associated with a higher risk of death and major bleeding. The efficacy and safety profile of dabigatran compared to warfarin was similar irrespective of renal function changes over time. Dabigatran 110 mg showed a greater relative risk reduction of major bleeding in patients with normal renal function during follow-up.
Source: American Heart Journal - January 6, 2018 Category: Cardiology Source Type: research

Outcomes of Apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
ConclusionsMulti-morbidity is prevalent among the population with AF; efficacy and safety of apixaban is preserved in this subgroup supporting extension of trial results to the most complex AF patients.Clinical trial registrationClinicalTrials.gov (NCT00412984).
Source: American Heart Journal - November 23, 2018 Category: Cardiology Source Type: research

Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease
ConclusionsNo statistically significant difference in the risk of ISSE or major bleeding was found between rivaroxaban- and warfarin-treated patients. While further study is needed, rivaroxaban appears to be a reasonable alternative to warfarin for ISSE prevention in the setting of NVAF and stage IV-V CKD.
Source: American Heart Journal - January 22, 2020 Category: Cardiology Source Type: research

Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study
Publication date: Available online 22 January 2021Source: American Heart JournalAuthor(s): Joris R. de Groot, Christian T. Ruff, Sabina A. Murphy, Rose A. Hamershock, Jim T. Vehmeijer, Anton J.M. Oude Ophuis, Laura Grip, Hans Lanz, Michele F. Mercuri, Elliott M. Antman, RobertP. Giugliano
Source: American Heart Journal - January 23, 2021 Category: Cardiology Source Type: research

Pages: 1  2  3  4